

Date: 14.08.2019

To,
1) BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001.

2) Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th Floor, Plot No. C62, Opp. Trident Hotel,
Bandrakurla Complex, Bandra (E), Mumbai-400098

3) Ahemdabad Stock Exchange Limited
Kamdhenu Complex, Opp. Sahajanad College,
Panjara Pole, Ambawadi, Ahmedabad - 380015

Dear Sir/Madam,

Sub: Outcome of board meeting under regulation 30 read with 33 (3) (c) of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015

Ref: Dr. Habeebullah Life Sciences Ltd (Scrip code: 539267)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of Dr. Habeebullah Life Sciences Ltd held on Wednesday, the 14th day of August, 2019 at 3.30P.M. at the registered office of the Company the following were duly considered and approved by the Board:

1. Un-Audited financial Statements (Standalone & Consolidated) for the quarter ended 30.06.2019.
2. Limited Review Report for the quarter ended 30.06.2019
3. Resignation of Mrs. Pooja Jain as company Secretary & Compliance officer of the company with effect from 13.08.2019.

The meeting of the Board of Directors commenced at 3.30 P.M.(IST) and concluded at 6.30 P.M.(IST).


This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Dr Habeebullah Life Sciences Ltd



K.Krishnam Raju
Whole-Time Director
(DIN: 00874650)



Encl: as above

Dr Habeebullah Life Sciences Ltd

(Formerly Known as PC Products India Limited)

PART-I		Rs in Lakhs				Consolidated
		STANDALONE & CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30TH JUNE, 2019				3 Months ended
S.No	Particulars	QUARTER ENDED			Previous Year Ended	3 Months ended
		3 Months ended	Preceding 3 months ended	Corresponding 3 months ended in	31-03-2019	30-06-2019
		30-06-2019	31-03-2019	previous year		
		UnAudited	Audited	UnAudited	Audited	UnAudited
I	Revenue from Operations	42.22	62.01	30.46	201.45	42.22
II	Other Income	-	11.05	-	11.05	-
III	Total Revenue (I+II)	42.22	73.05	30.46	212.49	42.22
IV	Expenses					
	Cost of Material Consumed	7.25	9.69	3.11	23.00	7.25
	Employee benefits expense	29.88	32.58	34.37	119.79	30.83
	Depreciation and Amortisation expense	0.24	0.67	0.09	0.94	0.24
	Other Expenses	65.12	76.21	55.66	282.31	72.93
	Total Expenses	102.49	119.15	93.23	426.05	111.25
V	Profit/(Loss) from before Exceptional Items and tax (I-IV)	(60.27)	(46.09)	(62.77)	(213.55)	(69.03)
VI	Exceptional Items					
VII	Profit/(Loss) before tax (V-VI)	(60.27)	(46.09)	(62.77)	(213.55)	(69.03)
VIII	Tax Expense:					
	Current Tax	-	-	-	-	-
	Deferred Tax	-	-	-	-	-
IX	Profit/ (Loss) for the period from Continuing operations (VII-VIII)	(60.27)	(46.09)	(62.77)	(213.55)	(69.03)
X	Profit/ (Loss) from discontinuing operations					
XI	Tax Expense of discontinuing operations					
XII	Profit/ (Loss) for the period from discontinuing operations after tax (X-XI)					
XIII	Profit/ (Loss) for the period (IX+XII)	(60.27)	(46.09)	(62.77)	(213.55)	(69.03)
XIV	Other Comprehensive Income					
	A) (i) Items that will not be reclassified to profit or loss					
	(ii) Income Tax related to items that will not be reclassified to profit or loss					
	B) (i) Items that will be reclassified to profit or loss					
	(ii) Income Tax relating to items that will be reclassified to profit or loss					
XV	Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (loss) and Other Comprehensive Income for the Period)	(60.27)	(46.09)	(62.77)	(213.55)	(69.03)
XVI	Earnings Per Equity Share (For Continuing Operations) (Face Value INR 10/- each)					
	1) Basic	(0.43)	(0.38)	(0.53)	(1.75)	(0.42)
	2) Diluted	(0.43)	(0.35)	(0.45)	(1.62)	(0.42)
XVII	Earnings Per Equity Share (For Discontinued Operations) (Face Value INR 10/- each)					
	1) Basic	-	-	-	-	-
	2) Diluted	-	-	-	-	-
XVIII	Earnings Per Equity Share (For Continued and Discontinued Operations)(Face Value INR 10/- each)					
	1) Basic	(0.43)	(0.38)	(0.53)	(1.75)	(0.42)
	2) Diluted	(0.43)	(0.35)	(0.45)	(1.62)	(0.42)
XIX	Paid Up Equity Share Capital (Face Value of INR 10/- per share)	1480.87	1380.87	1221.37	1380.87	1480.87

79



Notes:


- 1 The format for the Standalone & Consolidated Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.2(i) has been availed.
- 2 During the Quarter, the Company has converted 10,00,000 Convertible Warrants into Equity Shares to Promoters of the Company.
- 3 The Company has only one reportable segment i.e., Health Care Sector. Hence, the separate disclosure on Segment information is not required.
- 4 The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on **Wednesday, 14th August, 2019**.
- 5 The Standalone & Consolidated Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors of the Company.
- 6 Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 7 Effective April 01, 2019, the Company has adopted Ind AS 116 "Leases", applied to all the lease contracts existing on April 01, 2019 using the modified retrospective method. The adoption of the standard did not have any material impact on the financial results of the company for the quarter ended June 30, 2019.
- 8 The results are also available on the website of the Company www.drhlsl.com

Place : Hyderabad
Date : 14th August, 2019

For DR HABEEBULLAH LIFE SCIENCES LIMITED



K. Krishnam Raju
Executive Chairman (DIN 00874650)



Independent Auditor's Review Report on unaudited quarterly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors

Dr Habeebullah Life Sciences Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Dr Habeebullah Life Sciences Limited** ('the Company') for the quarter ended **June 30, 2019** and the year to-date results for the period **April 1, 2019 to June 30, 2019** ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether financial results are free of material misstatements. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulation including the manner in which it is to be disclosed, or that it contains any material misstatement.

For MSKA & Associates

Chartered Accountants

ICAI Firm Registration No.105047W



Ananthakrishnan G

Partner

Membership No.: 205226

UDIN: 19205226AAAABN2801

Place: Hyderabad

Date: August 14, 2019

